PaxGenBio Accelerates Global Market Expansion with Innovative Molecular Diagnostics Solutions at MEDICA 2024
PaxGenBio's promotional booth at MEDICA 2024, the world's largest medical device exhibition, showcases various products.
DÜSSELDORF, Germany--(Newswire) November 14, 2024 -- PaxGenBio, an innovative solution combining molecular diagnostics and immunodiagnostics, participated in MEDICA 2024, the world's largest medical device exhibition, to showcase its latest diagnostic technologies and strategies for global market expansion.
MPCR-ULFA-based infectious disease diagnostic kits highlighted as innovative multiplex diagnostic technology
At MEDICA 2024, PaxGenBio highlighted the PaxView® STI 12 MPCR-ULFA Kit and the PaxView® HPV30 Genotyping MPCR-ULFA Kit. The PaxView® STI 12 MPCR-ULFA Kit can simultaneously diagnose 12 sexually transmitted infectious diseases in a single test. At the same time, the PaxView® HPV30 Genotyping MPCR-ULFA Kit can genotype 30 human papillomavirus (HPV) strains, including 14 high-risk HPV strains, along with the presence of cervical cancer.
PaxGenBio's core technology, the MPCR-ULFA (Multiplex PCR-Universal Lateral Flow Assay) platform, has attracted great attention from overseas buyers by increasing efficiency and diagnostic reliability through multi-gene detection.
In addition, we introduced new products such as the real-time PCR product PaxView® STI12 FMCA (Fluorescence Melting Curve Analysis) kit and the nucleic acid extraction reagent GeneFlexTM Viral/Bacterial NA Extraction kit.
Company representatives consult with overseas buyers and take commemorative photos at PaxGenBio's booth at MEDICA 2024, the world's largest medical device exhibition.
Expanding Global Network, Accelerating Global Market Share Expansion
Through MEDICA 2024, PaxGenBio is aiming to strengthen cooperation with overseas distribution partners in Europe, the Middle East, and Asia, and is further refining its global expansion strategy. In particular, the exhibition was an important opportunity for the company to directly introduce its various diagnostic products to overseas medical professionals from the United Kingdom, Czech Republic, Brazil, Iran, India, Mexico, and other countries, and to establish cooperative relationships with major bio and medical device distributors. With this international network, PaxGenBio will provide customized diagnostic solutions tailored to the characteristics and needs of each region and accelerate its global market share expansion.
Maximizing Diagnostic Efficiency in Healthcare Settings with Innovative Diagnostic Technology
MPCR-ULFA technology is the world's first multi-rapid molecular diagnostic technology that combines molecular diagnostics and immunodiagnostic technologies to detect multiple genes simultaneously in a single test, enabling rapid and accurate gene detection of various infectious diseases. The PaxView® ULFA Reader enables automated analysis, increasing test speed and accuracy while providing ease of use. With this technology, PaxGenBio enables healthcare organizations to provide rapid diagnosis and early treatment.
PaxGenBio's promotional booth introduces its core technology, MPCR-ULFA (Multiplex PCR-Universal Lateral Flow Assay) platform.
PaxGenBio's participation in MEDICA 2024 provided a valuable opportunity to introduce its latest technology and expand collaborations with partners in Europe and beyond. PaxGenBio will continue to develop customized strategies and partnerships to meet the diverse diagnostic needs of the global bio market, including R&D collaborations with partners in India.
Meanwhile, PaxGenBio is growing in the global bio market by developing innovative molecular diagnostic products aimed at early diagnosis and prevention of diseases and supplying them to medical institutions around the world.
SOURCE: DUESSELDORF, Germany (Newswire) November 14, 2024
이전글
다음글